Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.
暂无分享,去创建一个
N Urban | B. Karlan | N. Urban | M. McIntosh | C. Drescher | I. Hellstrom | K. Hellstrom | N. Scholler | M W McIntosh | C Drescher | B Karlan | N Scholler | K E Hellstrom | I Hellstrom | Martin W. McIntosh | Nathalie Scholler | Ingegerd Hellstrom
[1] M R Conaway,et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. , 1995, Gynecologic oncology.
[2] N. Urban,et al. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. , 2003, Biostatistics.
[3] D. Singer,et al. Quantifying the potential benefit of CA 125 screening for ovarian cancer. , 1991, Journal of clinical epidemiology.
[4] D. Pauler,et al. Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers , 2001 .
[5] R. Bast,et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. , 1988, Gynecologic oncology.
[6] R. Bast,et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers , 1995, Cancer.
[7] R. Bast,et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. , 1999, Gynecologic oncology.
[8] N. Yamaguchi,et al. Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*) , 1995, The Journal of Biological Chemistry.
[9] Nicole Urban,et al. Generating longitudinal screening algorithms using novel biomarkers for disease. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[10] I. Pastan,et al. Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR‐3) cell line , 1994, International journal of cancer.
[11] Z. Ye,et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] Margaret Sullivan Pepe,et al. Combining Several Screening Tests: Optimality of the Risk Score , 2002, Biometrics.
[13] Kathleen A. Cronin,et al. Changepoint Modeling of Longitudinal PSA as a Biomarker for Prostate Cancer , 1997 .
[14] Ian J. Jacobs,et al. SCREENING FOR OVARIAN CANCER : A PILOT RANDOMISED CONTROLLED TRIAL , 1999 .
[15] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[16] O. Valenta,et al. Gynecologic oncology , 1990 .
[17] R. Bast,et al. Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer , 1986, Obstetrics and gynecology.
[18] R. Bast,et al. Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer , 1992, Obstetrics and gynecology.
[19] Peter E. Rossi,et al. Case Studies in Bayesian Statistics , 1998 .
[20] I. Pastan,et al. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. , 1992, Cancer research.
[21] B. Karlan,et al. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[22] U Menon,et al. Factors influencing serum CA125II levels in healthy postmenopausal women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.